OAM
TPTX

Oppenheimer Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Oppenheimer Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,015
Closed -$246K – 1218
2020
Q4 		$246K Buy
+2,015
New +$221K ﹤0.01% 1028
2020
Q2 		– Sell
-2,216
Closed -$99K – 1490
2020
Q1 		$99K Sell
2,216
-17
-0.8% -$903 ﹤0.01% 1109
2019
Q4 		$139K Buy
+2,233
New +$106K ﹤0.01% 1135

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Oppenheimer Asset Management's TPTX Position: Q1 2021 in Review

Oppenheimer Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2021, closing a stake of 2,015 shares — an estimated $246K sold.

Oppenheimer Asset Management first reported a position in TPTX in Q4 2019 and held it in 3 quarters. The position peaked at $246K in Q4 2020. 202 funds tracked by Wall St. Rank hold TPTX as of Q1 2021.

  • Oppenheimer Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Oppenheimer Asset Management sold 2,015 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $246K.
  • Oppenheimer Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • Oppenheimer Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $246K in Q4 2020.
  • 202 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Oppenheimer Asset Management's 13F filing for Q1 2021, filed 17 May 2021.